List view / Grid view

Issue 5 2012

Filter the results

 

article

Rapid micro methods and the next generation in ATP bioluminescence

25 October 2012 | By Michael J. Miller, President, Microbiology Consultants, LLC and Noe Miyashita, Researcher, Hitachi Plant Technologies, Ltd

This is the fifth paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2012. As many of you know, I am always on the lookout for the next generation of rapid microbiological method (RMM) technologies and solutions. In this article, I…

article

qPCR In-Depth Focus 2012

24 October 2012 | By

In this qPCR In-Depth Focus: Setting the bar; Q & A - Mikael Kubista from the TATAA Biocenter poses five questions for Jay Brock, Senior Manager, Applications and Technical Support, USB® Life Science Reagents from Affymetrix; Not your grandfathers’ real-time PCR...

article

Biologics: Teamwork pays off in race to expand market for monoclonal antibodies

22 October 2012 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune

The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from…

article

Applications of MRI to controlled drug delivery devices

22 October 2012 | By Mick Mantle, Department of Chemical Engineering & Biotechnology, University of Cambridge

Magnetic resonance imaging (MRI) is a technique that is traditionally used as a diagnostic clinical imaging tool. However, there are now an increasing number of non-medial applications where MRI has seen unrivalled success. One of those areas is in its application to pharmaceutical research. The aim of this article is…

article

Controlled nucleation in freeze-drying

22 October 2012 | By Henning Gieseler, Associate Professor at the Division of Pharmaceutics, University of Erlangen & CEO, GILYOS GmbH and Peter Stärtzel, Pharmaceutical Scientist, GILYOS GmbH

The stochastic nature of nucleation during the freezing step of the freeze-drying process has been regarded as a demerit in a process which is considered under rigorous control. The freezing performance of a product can impact its subsequent drying behaviour and the final product quality attributes. Hence, the idea to…

article

Preparing biocompatible materials for non-permanent medical devices

22 October 2012 | By Vinod B. Damodaran and Jessica M. Joslin, Department of Chemistry, Colorado State University and Melissa M. Reynolds, Department of Chemistry and School of Biomedical Engineering, Colorado State University

Biodegradable polymers comprise an important class of biomaterials due to their ability to satisfy short-term requirements for medical applications where a permanent implant is not required. However, current biodegradable polymers suffer from undesirable chemical properties that lead to improper elimination from the body and potentially toxic by-products. Additionally, medical polymers…

article

Evolving landscape of pharmaceutical outsourcing in China

22 October 2012 | By Xiaorong He, Senior Research Fellow, Boehringer-Ingelheim

China’s economic growth has shocked and awed the world, with its GDP growing at an average rate of 10 per cent for 30 years. The astonishing economic growth has also spurred rapid growth of pharmaceutical outsourcing business in China. In the past, China had been the major source of raw…